从2010版中国高血压指南看高血压合并冠心病患者的降压治疗策略.ppt

* 将HOPE和ONTARGET研究综合来看，美卡素80mg一片，可以减少心血管高危患者心血管死亡风险26%，减少心梗发生风险13%，减少卒中发生风险37%。相当于经您诊治过的1000个心血管高危患者，5年后，因为心血管死亡的人数减少19人，心血管事件发生减少37例。 Reference Yusuf S, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. The HOPE Study Investigators. N Engl J Med 2000;342:145–153. 2009年11月，欧盟药品评审局（EMEA）正式批准美卡素?（替米沙坦）新适应症，即美卡素可用于降低以下患者的心血管疾病发病率： 动脉粥样硬化性心血管疾病（冠心病、卒中、外周动脉疾病史） 2型糖尿病伴靶器官损害 截止2009年12月，美国（FDA）、加拿大、阿根廷、墨西哥、巴拉圭、玻利维亚、智利、 菲律宾、泰国和乌拉圭等国相继批准了美卡素相似适应症。 ONTARGET研究在中国入组了1600名患者，占全球总入组病人数约5%。基于ONTARGET研究中国人群的数据，美卡素全面心血管保护的新适应症在中国SFDA的申请也在进行当中。 * * This slide compares approved indications for ARBs in the European Union. Only telmisartan is indicated in CV high-risk patients, with manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or diabetes with documented target organ damage All licensed ARBs are indicated for the treatment of essential hypertension. Two ARBs, olmesartan and eprosartan are only indicated for the treatment of hypertension. Losartan is indicated for:1 Treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus with proteinuria as part of an antihypertensive medicinal product regimen Treatment of chronic heart failure (in patients 60 years), when treatment with angiotensin converting enzyme (ACE) inhibitors is not considered suitable due to incompatibility, especially cough, or contraindication. Reduction in the risk of stroke in adult hypertensive patients with left ventricular hypertrophy documented by ECG. Irbesartan is indicated for the treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.2 Valsartan is indicated for:1 Treatment of clinically stable patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfu